Progyny (NASDAQ:PGNY – Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Progyny to post earnings of $0.14 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Progyny (NASDAQ:PGNY – Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business had revenue of $269.94 million for the quarter, compared to the consensus estimate of $274.08 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Progyny Trading Up 2.0 %
Shares of PGNY opened at $33.06 on Wednesday. Progyny has a twelve month low of $29.44 and a twelve month high of $44.95. The company has a market cap of $3.18 billion, a P/E ratio of 53.32, a P/E/G ratio of 1.31 and a beta of 1.51. The company’s fifty day simple moving average is $34.95 and its 200-day simple moving average is $35.62.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on PGNY
Insider Activity
In other news, President Michael E. Sturmer sold 6,395 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.60, for a total value of $240,452.00. Following the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, President Michael E. Sturmer sold 6,395 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.60, for a total value of $240,452.00. Following the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman David J. Schlanger sold 71,272 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the completion of the sale, the chairman now owns 86,312 shares in the company, valued at $3,262,593.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,770 shares of company stock worth $3,853,985. Corporate insiders own 12.30% of the company’s stock.
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Read More
- Five stocks we like better than Progyny
- Consumer Staples Stocks, Explained
- Garmin Navigates to New Highs Driven By Wearables Trend
- P/E Ratio Calculation: How to Assess Stocks
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Energy and Oil Stocks Explained
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.